Phase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers
/in Clinical Trial, Metastatic, Phase 1/by MaxAAA817 (225Ac-PSMA-617) Phase2/3 Trial Will Start Recruiting Soon
/in Clinical Trial, Metastatic, Phase 2/by MaxIPH4502 Phase 1 Clinical Trial for Solid Tumors Expressing Nectin-4
/in Clinical Trial, Metastatic, Phase 1/by MaxWe can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues
/in Clinical Trial, Metastatic, Phase 1/by MaxUpdate on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025
/in Clinical Trial, Metastatic, Phase 1/by MaxVIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Clinical Trial for ADRX-0405 in Advanced Solid Tumors Including Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026